AbbVie Inc.

“AbbVie is a solid large-cap biopharma business with strong cash generation, proven commercial execution, and a credible post-Humira transition led by Skyrizi and Rinvoq. However, its economics remain tied to patent-protected franchises, balance-sheet quality is only moderate, and the current valuation does not offer a clear margin of safety for a long-term investor seeking exceptional compounding. The shares are investable, but not attractive enough today to justify high-conviction new capital.”